Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B | P18089 | 2/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.53 |
| ▸ | MAOB | P27338 | 6/20 | 0.50 |
| ▸ | MAOA | P21397 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | SNCA | P37840 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzphetamine SCHEMBL49120 | 0.79 | ADRA2B (1.00) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL19285634 | 0.79 | ADRA2B (1.00) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL678807 | 0.79 | ADRA2B (1.00) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL265137 | 0.78 | ADRA2B (0.96) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL260091 | 0.78 | ADRA2B (0.96) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| SCHEMBL8259850 | 0.78 | RIPK1 (0.45) | MAOBTSHRKDM4EMEN1KMT2A | |
| Benzphetamine SCHEMBL6272098 | 0.78 | ADRA2B (0.96) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL28360250 | 0.78 | ADRA2B (0.96) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL4329836 | 0.76 | ADRA2B (0.92) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| SCHEMBL25153031 | 0.75 | ALOX5 (0.50) | MAOBTSHRMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1568 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20200060997-A1 | TARR Receptor Agonists for Sexual Dysfunction | JOHN MCCOY | 2020-02-27 | — | — | US | claimed |
| EP-3366306-A2 | USE OF SOME PEPTIDES IN DIAGNOSIS AND TREATMENT OF DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-08-29 | — | — | EP | claimed |
| EP-3351262-A1 | CURAGLUTIDE FOR IN TREATMENT OF PREDIABETES, DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-07-25 | — | — | EP | claimed |
| US-20170348303-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2017-12-07 | — | — | US | claimed |
| US-9789105-B2 | Pharmaceutical compositions | LOCL PHARMA, INC. (US) | 2017-10-17 | — | — | US | claimed |
| US-9770514-B2 | Tamper-resistant pharmaceutical dosage forms | ExxPharma Therapeutics LLC (US) | 2017-09-26 | — | — | US | claimed |
| US-20160067271-A1 | Methods And Compositions For Preventing Or Treating Obesity | NORTHEASTERN UNIVERSITY | 2016-03-10 | — | — | US | claimed |
| US-20160051474-A1 | PHARMACEUTICAL COMPOSITIONS | LOCL PHARMA, INC. | 2016-02-25 | — | — | US | claimed |
| US-20160000815-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CT HOLDINGS PTY LTD (AU) | 2016-01-07 | — | — | US | claimed |
| WO-2003063781-A2 | SUBSTITUTED IMIDAZOLES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-08-07 | — | — | WO | claimed |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2003-06-19 | — | — | US | claimed |
| WO-2003045313-A2 | 2-AMINOQUINOLINE COMPOUNDS | MERCK & CO. INC. (US) | 2003-06-05 | — | — | WO | claimed |
| WO-2003045920-A1 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO., INC. (US) | 2003-06-05 | — | — | WO | claimed |
| WO-2003007887-A2 | SUBSTITUTED IMIDAZOLES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-01-30 | — | — | WO | claimed |
| JP-2001524960-A | — | — | 2001-12-04 | — | — | JP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0977572-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 2000-02-09 | — | — | EP | claimed |
| WO-1998047513-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-10-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067271-A1 | Methods And Compositions For Preventing Or Treating Obesity | ADORA2A, ADORA3, ADORA1 | ADRA2B 33/4885ADRA2C 19/4885ADRA1A 22/4885 |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | ADRA2B 548/4885ADRA2C 387/4885ADRA1A 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.